(P035) Prognostic Factors of Early Deaths in Patients With Craniopharyngioma From the SEER Registry

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Craniopharyngioma-related death represents the most common cause of early deaths in both pediatric and adult patients. GTR and adjuvant RT do not appear to have a significant impact on OS within 5 years of diagnosis. Older age, black race, and adamantinomatous/papillary histologies are significant prognostic factors for early deaths after the diagnosis.

Yuan J. Rao, MD, Stephanie Perkins, MD, Jiayi Huang, MD; Washington University

PURPOSE: Craniopharyngioma is a locally invasive tumor that is challenging to resect, and the roles of aggressive surgery or adjuvant radiation therapy (RT) are unclear. The current study analyzed the Surveillance, Epidemiology, and End Results (SEER) registry to identify prognostic factors of early deaths after the diagnosis of craniopharyngioma, as well as to examine the impact of gross total resection (GTR) or adjuvant RT on overall survival (OS).

METHODS: The SEER database was queried for craniopharyngioma patients from 2004 to 2011. Inclusion criteria included histologically confirmed craniopharyngioma with adequate information on age, surgical extent, and adjuvant RT. Patients who were aged < 3 years or > 69 years were excluded. Follow-up time was determined from the time of diagnosis. Cox proportional hazards models were used for univariate analysis (UVA) and multivariate analysis (MVA). OS rates were calculated using the Kaplan-Meier method and compared between groups using log-rank statistics.

RESULTS: A total of 788 patients met the inclusion criteria, and the median follow-up was 38 months (range: 1–95 mo). Nine pediatric patients died within 5 years of diagnosis, with 78% attributed to craniopharyngioma. Further, 81 adult patients died within 5 years of diagnosis, and the two most common causes of death were craniopharyngioma (36%) and cardiac/diabetic causes (31%). On both UVA and MVA, older age (hazard ratio [HR] = 1.03; 95% confidence interval [CI], 1.02–1.04), black race (HR = 3.52; 95% CI, 2.29–5.40), adamantinomatous histology (HR = 1.84; 95% CI, 1.19–2.84), and papillary histology (HR = 2.07; 95% CI, 1.12–3.82) were significant predictors of worse OS. In contrast, gender, GTR, adjuvant RT, and tumor size were not significantly correlated with OS. Adult patients (aged ≥ 18 yr) had significantly worse 5-year OS than pediatric patients (80% vs 95%, respectively; P < .01). Patients of black race had significantly worse 5-year OS than patients of other races (67% vs 87%, respectively; P < .01). Adamantinomatous histology and papillary histology were associated with worse 5-year OS than classic craniopharyngioma histology (80% and 77% vs 88%, respectively; P = .05). Patients with GTR had a 5-year OS of 83%, while those with biopsy or subtotal resection had a 5-year OS of 86% (P = .26). Patients with adjuvant RT had a 5-year OS of 89%, while those who did not receive RT had a 5-year OS of 83% (P = 0.15).

CONCLUSIONS: Craniopharyngioma-related death represents the most common cause of early deaths in both pediatric and adult patients. GTR and adjuvant RT do not appear to have a significant impact on OS within 5 years of diagnosis. Older age, black race, and adamantinomatous/papillary histologies are significant prognostic factors for early deaths after the diagnosis.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content